ACT-AD Phase 2 Trial Fully Enrolled with Results Expected Next Year

ACT-AD Phase 2 Trial Fully Enrolled with Results Expected Next Year

310270

ACT-AD Phase 2 Trial Fully Enrolled with Results Expected Next Year

Athira Pharma has completed enrollment in its ACT-AD Phase 2 trial evaluating the safety and efficacy of ATH-1017 in adults with mild-to-moderate Alzheimer’s disease. “The completion of enrollment in our ACT-AD trial is an important step forward in advancing ATH-1017 as a potential new treatment option for patients suffering from Alzheimer’s and other dementias,” Mark Litton, PhD, Athira president and CEO, said in a press release. “As part of our overall clinical development program to…

You must be logged in to read/download the full post.